154 related articles for article (PubMed ID: 31732223)
1. Quality of Life after Radioembolization for Hepatocellular Carcinoma Using a Digital Patient-Reported Outcome Tool.
Salem R; Hassan S; Lewandowski RJ; Grace K; Martin RCG; Sichlau MJ; Fung J; Kim E; Chao S; Rosner BI
J Vasc Interv Radiol; 2020 Feb; 31(2):311-314.e1. PubMed ID: 31732223
[TBL] [Abstract][Full Text] [Related]
2. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
[TBL] [Abstract][Full Text] [Related]
4. Acute Biliary Obstruction after Transarterial Radioembolization with Yttrium-90.
Ghosn M; Mulé S; Chalaye J; Tacher V; Calderaro J; Luciani A; Amaddeo G
J Vasc Interv Radiol; 2019 Dec; 30(12):2043-2045. PubMed ID: 31668969
[No Abstract] [Full Text] [Related]
5. Focus on Uniformity, Not Dose: The Folly of Yttrium-90 Transarterial Radioembolization Dose-Escalation Studies.
Nuffer Z
J Vasc Interv Radiol; 2024 Jun; 35(6):918-919. PubMed ID: 38447769
[No Abstract] [Full Text] [Related]
6. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.
Gabr A; Abouchaleh N; Ali R; Baker T; Caicedo J; Katariya N; Abecassis M; Riaz A; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2018 Nov; 29(11):1502-1510.e1. PubMed ID: 30268638
[TBL] [Abstract][Full Text] [Related]
8. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
9. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score.
Bargellini I; Scalise P; Boni G; Traino CA; Bozzi E; Lorenzoni G; Crocetti L; Cioni R
J Vasc Interv Radiol; 2020 Dec; 31(12):2028-2032. PubMed ID: 33121865
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
[TBL] [Abstract][Full Text] [Related]
12. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
14. Coil-Assisted Temporary Vascular Occlusion to Protect Tumor-Free Territory during Transarterial Radioembolization.
Park JJ; Boas FE
J Vasc Interv Radiol; 2024 Jun; 35(6):929-931. PubMed ID: 38789206
[No Abstract] [Full Text] [Related]
15. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
16. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
17. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
20. Ablative Transarterial Radioembolization of a Parasitized Adrenal Artery for the Treatment of Hepatocellular Carcinoma.
Vidal LLC; Frey GT; Ritchie C; Lewis A; Paz-Fumagalli R; McKinney M; Toskich BB
J Vasc Interv Radiol; 2019 Mar; 30(3):473-476. PubMed ID: 30819498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
